Replimune (REPL) Free Cash Flow (2017 - 2025)
Replimune's (REPL) quarterly Free Cash Flow came in at -$66.1 million in Q4 2025, down 39.82% year-on-year from -$109.8 million in Q4 2024, and up 21.93% quarter-over-quarter from -$84.6 million in Q3 2025.
Replimune (REPL) Free Cash Flow (2017 - 2025) Analysis & Trends
Replimune has disclosed Free Cash Flow across 9 years of filings, most recently posting -$66.1 million for Q4 2025.
- Free Cash Flow for Q4 2025 came in at -$66.1 million, down 39.82% year-over-year; the trailing twelve-month figure through Dec 2025 was -$288.5 million (down 51.43% YoY), and the FY2025 annual result was -$198.9 million, down 4.09% from the prior year.
- Free Cash Flow came in at -$66.1 million for Q4 2025 at Replimune, up from -$84.6 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$16.1 million in Q1 2021 to a low of -$84.6 million in Q3 2025.
- The 5-year median for Free Cash Flow is -$42.9 million (2023), against an average of -$42.4 million.
- Across the five-year window, Free Cash Flow increased 10.26% in 2024 and sank 107.87% in 2025, its largest moves.
- Replimune's Free Cash Flow stood at -$18.8 million in 2021, then slumped by 44.28% to -$27.1 million in 2022, then tumbled by 65.96% to -$45.0 million in 2023, then decreased by 4.93% to -$47.3 million in 2024, then tumbled by 39.82% to -$66.1 million in 2025.
- The last three Free Cash Flow figures came in at -$66.1 million (Q4 2025), -$84.6 million (Q3 2025), and -$77.7 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 63,220.27 |
| 10 | Replimune | 780.01 Mn | 510.88 Mn | - | -66.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -66.09 Mn |
| Dec 31, 2025 | -66.09 Mn |
| Sep 30, 2025 | -84.65 Mn |
| Sep 30, 2025 | -84.65 Mn |
| Jun 30, 2025 | -77.66 Mn |
| Jun 30, 2025 | -77.66 Mn |
| Mar 31, 2025 | -60.11 Mn |
| Mar 31, 2025 | -60.11 Mn |
| Dec 31, 2024 | -47.27 Mn |
| Dec 31, 2024 | -47.27 Mn |
| Sep 30, 2024 | -40.72 Mn |
| Sep 30, 2024 | -40.72 Mn |
| Jun 30, 2024 | -50.84 Mn |
| Jun 30, 2024 | -50.84 Mn |
| Mar 31, 2024 | -51.70 Mn |
| Mar 31, 2024 | -51.70 Mn |
| Dec 31, 2023 | -45.05 Mn |
| Dec 31, 2023 | -45.05 Mn |
| Sep 30, 2023 | -45.38 Mn |
| Sep 30, 2023 | -45.38 Mn |